T/R potency <5% [Regulatives / Guidelines]

posted by Achievwin – US, 2022-09-07 22:50 (982 d 04:55 ago) – Posting: # 23277
Views: 4,386

❝ ❝ Somewhere in the Bioequivalence guidance I remembered that when designing the studies we try to keep T/R potency +/-5%. Can someone point out where this kind of condition existed, (latest guidance has no mention of this)


❝ – AFAIK, it was never stated by the FDA in any guidance.


It was there in 2001 guidance as desired requirement-not mandatory... problem is that I can not find that 2001 (first) BE/BA guidance
I can not find that 2001 (first) BE/BA guidance. Also in 2021 guidance lines 807-808

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
164 visitors (0 registered, 164 guests [including 12 identified bots]).
Forum time: 03:46 CEST (Europe/Vienna)

By all means let’s be open-minded, but not so open-minded
that our brains drop out.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5